Tradestie Institutional Equity Comparison Engine · Market Close Sep 23, 2026

TBPH vs XOMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TBPH Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

TBPH Overall Winner 6-Pillar Tally: TBPH 3 – 2 XOMA (1 Tie) Matrix Metrics: TBPH 6 – 4 XOMA

As of Sep 23, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over XOMA Royalty Corporation (XOMA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin).

  • Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. TBPH 54.9/100 HOLD), TBPH captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (8.9% vs. -3.9% operating margin) and revenue trajectory (-20.9% vs. -22.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TBPH vs XOMA
TBPH NASDAQ Head-to-Head Winner
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
TTM Revenue $104M
Forward P/E 13.4x
Beta / 30D Vol 0.48β · 2% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $17.04 · SMA50: $16.96
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06

6-Pillar Scorecard Institutional Category Breakdown (TBPH 3 – 2 XOMA)

Columns: Metric · TBPH · XOMA
1. Valuation Multiples TBPH
Forward P/E 13.4x 21.5x
Trailing P/E 16.4x 28.2x
PEG Ratio N/M N/M
EV / Revenue 8.5x 16.1x
2. Growth & Scale TBPH
Revenue Growth (YoY) -20.9% -22.6%
Earnings Growth (YoY) +0.0% +207.9%
TTM Revenue (USD) $104M $49M
Market Cap $884.2M $781.8M
3. Profitability & Quality XOMA
Gross Margin 75.1% 99.0%
Operating Margin 8.9% -3.9%
Net Profit Margin 51.6% 69.6%
Return on Equity (ROE) 20.9% 34.2%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) $11M EBITDA $8.3M EBITDA
Cash Flow Margin 10.6% EBITDA Mgn 17.1% EBITDA Mgn
Net Cash / Leverage $5.58 Book/Sh · 20.9% ROE $7.79 Book/Sh · 34.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 55.0% (16th %ile) 101.5% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TBPH
OpEx & R&D Intensity 66.2% of Rev ($69M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TBPH (6) vs XOMA (4)
Institutional Metric TBPH XOMA Criterion Row Edge
Market Capitalization
Scale
$884.2M $781.8M Larger Scale TBPH
Trailing P/E Ratio
Valuation
16.4x 28.2x Lower Multiple TBPH
Forward P/E Ratio
Valuation
13.4x 21.5x Lower Multiple TBPH
Revenue Growth (YoY)
Growth
-20.9% -22.6% Higher Growth TBPH
Operating Margin (TTM)
Profitability
8.9% -3.9% Higher Margin TBPH
Net Profit Margin
Profitability
51.6% 69.6% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
20.9% 34.2% Higher ROE XOMA
52-Week Range Position
Momentum
50% ($13–$21) 78% ($22–$45) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.48β · 2% Vol 0.68β · 37% Vol Lower Realized Risk TBPH
Unified Institutional Score
Composite Signal
54.9 / 100 (HOLD) 55.8 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$104M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.1% 99.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.5x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$11M EBITDA ($5.58 Book/Sh · 20.9% ROE) $8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TBPH +7.05 pp
TBPH: +3.24% · XOMA: -3.81%
3M Horizon XOMA +5.98 pp
TBPH: +3.36% · XOMA: +9.34%
6M Horizon XOMA +45.41 pp
TBPH: -11.15% · XOMA: +34.26%
1Y Horizon TBPH +12.01 pp
TBPH: +20.11% · XOMA: +8.1%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TBPH vs XOMA. Trailing 12-month operating profitability (TBPH 8.9% vs XOMA -3.9%) and valuation multiples (TBPH 13.4x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

TBPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$104M
Gross Margin75.1%
Op. Margin8.9%
ROE / Fwd P/E20.9% · 13.4x
XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TBPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.0%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TBPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TBPH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($69M)
90D Engineering Disclosures 0 Published
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TBPH vs XOMA Key Questions & Quantitative Answers

As of Sep 23, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over XOMA Royalty Corporation (XOMA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin). Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. TBPH 54.9/100 HOLD), TBPH captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (8.9% vs. -3.9% operating margin) and revenue trajectory (-20.9% vs. -22.6% YoY).

TBPH leads the Growth & Scale pillar: TBPH posts -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, TBPH generates $104M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, TBPH deploys 66.2% of Rev ($69M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.

TBPH screens cheaper on headline valuation multiples. TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TBPH (20.9% ROE) versus XOMA (34.2% ROE) capital efficiency.

In options market volatility and institutional positioning, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Sep 23, 2026. For educational research only; not investment advice.